RxDoctor Payments Data

Nitin Pothen

Psychiatry · Brick, NJNPI 1821550948

Payments from drug & device makers

$3,056in general payments, 2019–2025

Across 182 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$317
  • Corium, LLC$208
  • Vanda Pharmaceuticals Inc.$208
  • Johnson & Johnson$202
  • Neurocrine Biosciences, Inc.$137
  • plus $839 from 17 others

What the payments were for

  • Food & beverage$3,00998%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,056 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$54,403
Medicare patients
180
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$45,854
VraylarCariprazine Hcl21$33,245
Paliperidone ErPaliperidone14$6,324
Aripiprazole86$5,397
Lurasidone Hcl20$5,388
Divalproex Sodium ErDivalproex Sodium37$4,632
Clozapine28$2,207
Duloxetine Hcl84$1,936
Bupropion XlBupropion Hcl94$1,465
Fluoxetine Hcl83$1,425
Olanzapine56$1,203
Trazodone Hcl121$1,111
Quetiapine Fumarate68$1,106
Gabapentin89$1,055
Armodafinil19$1,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$202$45,85413 claims
AbbVieVraylar$1,145$33,24521 claims
Lilly USA, LLCOlanzapine$45$1,20356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →